Is 'class effect' relevant when assessing the benefit/risk profile of a biologic agent?

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue SUPPL. 5, 2012, Pages 9-16

  Sterry, W ^a   Van De Kerkhof, P ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BCG VACCINE; BRIAKINUMAB; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 12P40; PLACEBO; TUMOR NECROSIS FACTOR; USTEKINUMAB;

ALLERGIC REACTION; ANTIBODY RESPONSE; ASTHENIA; BACTERIAL INFECTION; CANDIDIASIS; CONFERENCE PAPER; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG STRUCTURE; ERYTHRODERMA; GASTROINTESTINAL DISEASE; HUMAN; IMMUNE RESPONSE; INFECTION; INFECTION PREVENTION; INJECTION SITE REACTION; LOADING DRUG DOSE; MALAISE; MUSCULOSKELETAL PAIN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIASIS VULGARIS; RASH; RESPIRATORY TRACT INFECTION; RISK ASSESSMENT; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUBERCULOSIS; VERTIGO; VIRUS INFECTION;

BIOLOGICAL AGENTS; CYTOKINES; DERMATOLOGIC AGENTS; HALF-LIFE; HUMANS; PSORIASIS; T-LYMPHOCYTES;

EID: 84863660321     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04605.x     Document Type: Conference Paper

References (54)

1. Christophers E,. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-320.
2. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23: 1-70.
3. Smith CH, Anstey AV, Barker JN, et al.; Chair of Guideline Group. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
4. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486-497.
5. Nickoloff BJ, Nestle FO,. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113: 1664-1675.
6. Krueger JG,. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.
7. Chan AC, Carter PJ,. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10: 301-316.
8. Kindt TJ, Goldsby RA, Osbourne BA,. Immunology. 6th edn. WH Freeman and Company, New York, 2007.
9. Lebwohl M, Tyring SK, Hamilton TK, et al.; Efalizumab Study Group. cA novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-2013.
10. Gordon KB, Papp KA, Hamilton TK, et al.; Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290: 3073-3080.
11. Leonardi CL, Papp KA, Gordon KB, et al.; Efalizumab Study Group. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005; 52: 425-433.
12. Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141: 31-38.
13. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
14. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312.
15. Tyring S, Gottlieb AB, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35.
16. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB,. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-1847.
17. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-542.
18. Wang W, Wang WQ, Balthasar JP,. Monoclonal antibody pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 2008; 84: 548-558.
19. Guttman-Yassky E, Vugmeyster Y, Lowes MA, et al. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness. J Invest Dermatol 2008; 128: 1182-1191.
20. Krueger JG, Ochs HD, Patel P, et al. Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study. J Invest Dermatol 2008; 128: 2615-2624.
21. Sachs C, Benson J, Smith P, et al. Characterization of immune and asthmatic responses in cynomolgus macaques following antagonism of IL-12/23 activity with ustekinumab (CNTO 1275). Abstract 2141, presented at the 48th Annual Meeting and ToxExpo of the Society of Toxicology, Seattle, Washington, US. March 16-20, 2008.
22. European Medicines Agency [WWW document]. Scientific conclusions: Raptiva. London, 17 April 2009. URL (last accessed: 13 January 2011).
23. Jariwala SP,. The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res 2007; 299: 359-366.
24. Trinchieri G,. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat RevImmunol 2003; 3: 133-146.
25. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-957.
26. Lowes MA, Lew W, Krueger JG,. Current concepts in the immunopathogenesis of psoriasis. DermatolClin 2004; 22: 349-369, vii.
27. Krueger J,. Oral presentation at 2nd World Psoriasis & Psoriatic Arthritis Conference, 24-28 June 2009, Stockholm.
28. Etanercept European Summary of Product Characteristics. Date: March 2011.
29. Infliximab European Summary of Product Characteristics. Date: August 2011.
30. Adalimumab European Summary of Product Characteristics. Date: May 2011.
31. Giles-Komar J, et al. Centocor Ortho Biotech Inc. United States patent US 7560247. 2009 Jul 14.
32. Salfeld J, et al. Abbott GmbH & Co. KG. United States patent US 6914128. 2007 Jul 5.
33. Data on file. STE/DoF/Dec2010/EMEA010. Janssen EMEA, 2010.
34. Boehncke WH, Prinz J, Gottlieb AB,. Biologic therapies for psoriasis: a systematic review. J Rheumatol 2006; 33: 1447-1451.
35. Leonardi CL, Kimball AB, Papp KA, et al.; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674.
36. Ustekinumab European Summary of Product Characteristics. Date: March 2011.
37. Gordon K, Langley R, Gottlieb A, et al. Efficacy and safety results from a phase III, randomized controlled trial comparing two dosing regimens of ABT-874 to placebo in patients with moderate to severe psoriasis. Poster (P595) presented at the 19th congress of the European Academy of Dermatology and Venerology, Gothenberg, Sweden. 6-10 October, 2010.
38. Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 2009; 49: 162-175.
39. Lima XT, Abuabara K, Kimball AB, Lima HC,. Briakinumab. Expert Opin Biol Ther 2009; 9: 1107-1113.
40. Haider AS, Cardinale IR, Whynot JA, Kruegar JG,. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J Invest Dermatol Symp 2007; 12: 9-15.
41. Langley RG, Strober BE, Gu Y, et al. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol 2010; 162: 1349-1358.
42. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374.
43. Gottlieb AB, Leornardi CL, Gofe BS, et al. Etanerceptmonotherapy in patients in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 2006; 54: S92-S100.
44. Brimhall AK, King LN, Licciardone JC, et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 274-285.
45. Tubach F, Salmon D, Ravaud P, et al.; Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60: 1884-1894.
46. Salmon D,; GTI and AFSSAPS. Groupe Tuberculose et infliximab. Agence Française de Sécurité Sanitaire de Produits de Santé Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine 2002; 69: 170-172.
47. Sachs C, Imai N, Oneda S, et al. Absence of developmental toxicity in embryofetal and pre- and postnatal development studies in cynomolgus macaques following antagonism of IL-12/23 activity with ustekinumab (CNTO 1275). Abstract 1160, presented at the 48th Annual Meeting and ToxExpo of the Society of Toxicology, Seattle, Washington, US. March 16-20, 2008.
48. Bowcock AM, Kruegar JB,. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005; 5: 699-710.
49. Haider AS, Lowes MA, Suárez-Fariñas M, et al. Identification of cellular pathways of 'type 1,' Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 2008; 180: 1913-1920.
50. Nograles KE, Brasington RD, Bowcock AM,. New insights into the pathogenesis and genetics of psoriatic arthritis. Rheumatology 2009; 5: 83-91.
51. Lebwohl M, Bagel J, Gelfand JM, et al. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 2008; 58: 94-105.
52. Watson K, Symmons D, Griffiths I, Silman A,. The British society for rheumatology biologics register. Ann Rheum Dis 2005; 64: 42-43.
53. Hyrich KL, Watson KD, Isenberg DA,; Symmons DPM on behalf of the BSR Biologics Register. The British society for rheumatology biologics register: 6 years on. Rheumatology 2008; 47: 1441-1443.
54. Askling J, Fored CM, Geborek P, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006; 65: 707-712.